72033-13-7

Basic information

• Product Name: 2-(ISOQUINOLIN-3-YL)ACETIC ACID
• Synonyms: 2-(ISOQUINOLIN-3-YL)ACETIC ACID;Isoquinolin-3-yl-acetic acid
• CAS NO: 72033-13-7
• Molecular Formula: C11H9NO2
• Molecular Weight: 187.2
• Mol File: 72033-13-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 389°C at 760 mmHg
• Flash Point: 189.1°C
• Appearance: /
• Density: 1.297g/cm³
• Vapor Pressure: 9.5E-07mmHg at 25°C
• Refractive Index: 1.66
• PKA: 1.30±0.30(Predicted)
• CAS DataBase Reference: 2-(ISOQUINOLIN-3-YL)ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(ISOQUINOLIN-3-YL)ACETIC ACID(72033-13-7)
• EPA Substance Registry System: 2-(ISOQUINOLIN-3-YL)ACETIC ACID(72033-13-7)

Safety Data

• Hazardous Substances Data: 72033-13-7(Hazardous Substances Data)

Usage

Derivative of isoquinoline

The compound is based on the isoquinoline structure, which is a heterocyclic compound consisting of a benzene ring fused to a nitrogen-containing ring.

White crystalline powder

The physical appearance of the compound is a white crystalline powder.

Soluble in water and organic solvents

The compound can dissolve in both water and various organic solvents, which can be important for its pharmaceutical and chemical applications.

Potential pharmaceutical applications

2-(isoquinolin-3-yl)acetic acid has been studied for its potential as an anti-inflammatory and analgesic agent.

Structural similarity to other bioactive molecules

Due to its chemical structure, the compound may have potential as a building block in drug discovery and development.

Potential applications in chemical research and synthesis

The compound may also be useful in chemical research and synthesis, due to its unique structure and properties.

InChI:InChI=1/C11H9NO2/c13-11(14)6-10-5-8-3-1-2-4-9(8)7-12-10/h1-5,7H,6H2,(H,13,14)

Upstream product

• 58130-44-2 2-(isoquinolin-3-yl)acetonitrile 
• 54804-44-3 3-(Bromomethyl)isoquinoline 
• 1125-80-0 3-methylisoquinoline 
• 69391-35-1 C₁₁H₉NO₃ 

Relevant articles and documents

Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3′-carboxamido)morphinan analogues as opioid receptor ligands

A series of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3′-carboxamido)morphinan (NAQ) analogues were synthesized and pharmacologically characterized to study their structure-activity relationship at the mu opioid receptor (MOR). The competition binding assay showed two-atom spacer and aromatic side chain were optimal for MOR selectivity. Meanwhile, substitutions at the 1′- and/or 4′-position of the isoquinoline ring retained or improved MOR selectivity over the kappa opioid receptor while still possessing above 20-fold MOR selectivity over the delta opioid receptor. In contrast, substitutions at the 6′- and/or 7′-position of the isoquinoline ring reduced MOR selectivity as well as MOR efficacy. Among this series of ligands, compound 11 acted as an antagonist when challenged with morphine in warm-water tail immersion assay and produced less significant withdrawal symptoms compared to naltrexone in morphine-pelleted mice. Compound 11 also antagonized the intracellular Ca2+ increase induced by DAMGO. Molecular dynamics simulation studies of 11 in three opioid receptors indicated orientation of the 6′-nitro group varied significantly in the different 'address' domains of the receptors and played a crucial role in the observed binding affinities and selectivity. Collectively, the current findings provide valuable insights for future development of NAQ-based MOR selective ligands.

NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS

Selective, non-peptide antagonists of the ma opioid receptor { MOR) and methods of their use are provided. The antagonists may be used, for example, to identify MOR agonists in competitive binding assays, and to treat conditions related to addiction in which MOR is involved, e.g. heroin, prescription drug and alcohol addiction.